TABLE 1.
Patient characteristics
| Patient characteristics |
Number of patients (n = 37) |
|---|---|
| Age | |
| Median | 65 years |
| Range | 42–81 |
| Sex | |
| Male | 25 |
| Female | 12 |
| Vaccine | |
| BNT162b2 | 29 |
| mRNA‐1273 | 6 |
| Ad26.COV2.S | 2 |
| Time between diagnosis and vaccination (months) | |
| Median | 45 |
| Range | 2–314 |
| Therapy | |
| Previously untreated | 14 |
| BTK inhibitor | 15 |
| Venetoclax + anti‐CD20 antibody | 8 |
| Prior anti‐CD20 monoclonal antibody | |
| <12 months | 8 |
| ≥12 months | 11 |
| IgG (normal 610–1616) | |
| Median | 651 |
| Range | 70–1037 |
| Absolute lymphocyte count | |
| Median | 2.12 × 103/μl |
| Range | 0.52–306 × 103/μl |
| Normal B‐lymphocyte count | Median (range) |
| Previously untreated | 104 cells/μl (8–625 cells/μl) |
| BTK inhibitor | 0 cells/μl (0–121 cells/μl) |
| Venetoclax + anti‐CD20 antibody | 0 cells/μl (0–39 cells/μl) |